Want to see NVCT full AI Analyst Report?
NVCT Stock Chart & Stats
$23.73
$0.12(0.62%)
At close: 4:00 PM EDT
$23.73
$0.12(0.62%)
Day’s Range― - ―
52-Week Range$5.55 - $29.28
Previous CloseN/A
Volume13.30K
Average Volume (3M)206.96K
Market Cap
$715.56M
Enterprise Value$409.56M
Total Cash (Recent Filing)$22.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 10, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding32,644,066
10 Day Avg. Volume249,613
30 Day Avg. Volume206,961
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)8.94
Price to Sales (P/S)0.00
P/FCF Ratio-10.29
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-14.16
Forecast
1Y Price Target
$34.00Price Target Upside43.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure removes scheduled principal and interest obligations, preserving flexibility while the company funds clinical development. Positive recent equity also provides a current buffer against financial stress, although that cushion has declined as losses accumulated.
Precision Oncology FocusFocusing on genetically defined patient populations can support more precise clinical development and targeted therapeutic positioning. This strategy gives the pipeline a clear scientific direction and may improve the potential for differentiated products if candidates demonstrate clinical benefit.
Financing FlexibilityThe refreshed ATM facility gives Nuvectis a flexible mechanism to fund operations, clinical programs, or strategic needs without committing to a fixed issuance schedule. That access can extend execution capacity as development milestones require capital over the next several quarters.
Bears Say
Pre-revenue Business ModelWith no reported revenue, Nuvectis has not yet demonstrated product commercialization or recurring operating economics. Continued value creation therefore depends on advancing investigational candidates, while operating expenses remain unsupported by sales and profitability remains distant.
Persistent Cash BurnNegative operating and free cash flow in every period shows that the business consumes capital to sustain development. The worsening TTM burn increases dependence on additional funding and could constrain clinical execution if financing conditions or capital availability become less favorable.
Equity Dilution RiskUsing equity markets to fund ongoing losses and development can increase the number of shares outstanding, diluting existing holders over time. The large refreshed facility creates meaningful financing capacity, but also leaves dilution as a durable consideration while cash generation remains negative.
Nuvectis Pharma News
NVCT FAQ
What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $5.55 and its highest was $29.27 in the past 12 months.
What is Nuvectis Pharma’s market cap?
Nuvectis Pharma’s market cap is $715.56M.
When is Nuvectis Pharma’s upcoming earnings report date?
Nuvectis Pharma’s upcoming earnings report date is Nov 10, 2026 which is in 36 days.
How were Nuvectis Pharma’s earnings last quarter?
Nuvectis Pharma released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.262 by -$0.038.
Is Nuvectis Pharma overvalued?
According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued.
Does Nuvectis Pharma pay dividends?
Nuvectis Pharma does not currently pay dividends.
What is Nuvectis Pharma’s EPS estimate?
Nuvectis Pharma’s EPS estimate is -0.24.
How many shares outstanding does Nuvectis Pharma have?
Nuvectis Pharma has 32,644,066 shares outstanding.
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Nuvectis Pharma reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.262. Following the earnings report the stock price went down -6.944%.
Which hedge fund is a major shareholder of Nuvectis Pharma?
Currently, no hedge funds are holding shares in NVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvectis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (43.28% Upside)
$34.00 (43.28% Upside)
Blogger Sentiment
Bullish
NVCT Sentiment 67%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 8.6%
Last 30 Days ▲ 8.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
261.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.15%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nuvectis Pharma
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
NVCT Stock 12 Month Forecast
Average Price Target
$34.00
▲(43.28% Upside)
Technical Analysis
Nkarta
―
Orchestra BioMed Holdings
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
34.86% Insiders
3.61% Mutual Funds
18.14% Other Institutional Investors
36.91% Public Companies and
Individual Investors